TWI862564B - 癌治療用醫藥 - Google Patents

癌治療用醫藥 Download PDF

Info

Publication number
TWI862564B
TWI862564B TW109110983A TW109110983A TWI862564B TW I862564 B TWI862564 B TW I862564B TW 109110983 A TW109110983 A TW 109110983A TW 109110983 A TW109110983 A TW 109110983A TW I862564 B TWI862564 B TW I862564B
Authority
TW
Taiwan
Prior art keywords
antibody
amino acid
lenvatinib
acid sequences
chain
Prior art date
Application number
TW109110983A
Other languages
English (en)
Chinese (zh)
Other versions
TW202104259A (zh
Inventor
中村康司
高橋恒太
坂口泉
張霊
Original Assignee
日商凱依歐姆 生物科學股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商凱依歐姆 生物科學股份有限公司 filed Critical 日商凱依歐姆 生物科學股份有限公司
Publication of TW202104259A publication Critical patent/TW202104259A/zh
Application granted granted Critical
Publication of TWI862564B publication Critical patent/TWI862564B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW109110983A 2019-04-01 2020-03-31 癌治療用醫藥 TWI862564B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019070120 2019-04-01
JP2019-070120 2019-04-01

Publications (2)

Publication Number Publication Date
TW202104259A TW202104259A (zh) 2021-02-01
TWI862564B true TWI862564B (zh) 2024-11-21

Family

ID=72668636

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109110983A TWI862564B (zh) 2019-04-01 2020-03-31 癌治療用醫藥

Country Status (10)

Country Link
US (1) US20220193064A1 (https=)
EP (1) EP3949990A4 (https=)
JP (1) JP7549889B2 (https=)
KR (1) KR20210144767A (https=)
CN (1) CN113660954B (https=)
AU (1) AU2020255907A1 (https=)
CA (1) CA3135157A1 (https=)
IL (1) IL286680A (https=)
TW (1) TWI862564B (https=)
WO (1) WO2020204033A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4226945A4 (en) * 2020-10-05 2024-10-23 Chiome Bioscience, Inc MEDICINES FOR THE TREATMENT OF CANCER

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104704119B (zh) * 2012-10-03 2017-09-05 凯奥目生物科学株式会社 在体内具有抗肿瘤活性的抗人Dlk‑1抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
CN1304046C (zh) * 2004-06-29 2007-03-14 上海人类基因组研究中心 肝癌相关基因dlk1及其应用
CN103073641B (zh) * 2006-11-10 2015-01-21 株式会社立富泰克 在体内具有抗肿瘤活性的抗人Dlk-1抗体
ES2527521T3 (es) * 2008-03-17 2015-01-26 Livtech Inc. Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral
KR102091871B1 (ko) 2012-07-26 2020-03-20 덴카 주식회사 수지 조성물
SI3579883T1 (sl) * 2017-02-08 2021-12-31 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104704119B (zh) * 2012-10-03 2017-09-05 凯奥目生物科学株式会社 在体内具有抗肿瘤活性的抗人Dlk‑1抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Masatoshi Kudo ; Systemic Therapy for Hepatocellular Carcinoma: Latest Advances. Cancers 2018, 10, 412. p1-16. *

Also Published As

Publication number Publication date
CA3135157A1 (en) 2020-10-08
EP3949990A1 (en) 2022-02-09
KR20210144767A (ko) 2021-11-30
CN113660954B (zh) 2025-01-14
IL286680A (en) 2021-10-31
AU2020255907A1 (en) 2021-10-28
CN113660954A (zh) 2021-11-16
US20220193064A1 (en) 2022-06-23
JP7549889B2 (ja) 2024-09-12
JPWO2020204033A1 (https=) 2020-10-08
WO2020204033A1 (ja) 2020-10-08
TW202104259A (zh) 2021-02-01
EP3949990A4 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
JP7259104B2 (ja) 抗ｔｒｏｐ２抗体－薬物コンジュゲート
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
ES2708124T3 (es) Procedimiento para preparar moléculas heteromultiméricas
KR20120060235A (ko) 특이성 결합 단백질 및 용도
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
JP7469305B2 (ja) 抗ｐｄ－１抗体およびその使用
TW201813671A (zh) 抗ｃ－Ｍｅｔ抗體－細胞毒性藥物偶聯物的醫藥用途
TWI862564B (zh) 癌治療用醫藥
US20230398227A1 (en) Medicine for treating cancer
KR20240072932A (ko) B7-h3에 특이적으로 결합하는 항체
HK40092141A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
HK40090814A (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
WO2026052782A1 (en) Anti-globo h antibodies
CN118324916A (zh) 一种抗人gprc5d的单克隆抗体及其制备方法和用途